T
Tsutomu Kasugai
Researcher at Osaka University
Publications - 100
Citations - 5527
Tsutomu Kasugai is an academic researcher from Osaka University. The author has contributed to research in topics: Breast cancer & Mast cell. The author has an hindex of 36, co-authored 99 publications receiving 5413 citations. Previous affiliations of Tsutomu Kasugai include Kyoto Prefectural University of Medicine.
Papers
More filters
Journal ArticleDOI
Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Noriko Fujita,Yukie Enomoto,Keiko Inakami,Tetsu Yanagisawa,Chikage Iguchi,Toyokazu Aono,Takashi Nomura,Hitoshi Yamamoto,Tsutomu Kasugai,Eiichi Shiba +9 more
TL;DR: Positive clinical nodal status and young age were found to be prognostic factors before and after neoadjuvant chemotherapy among HER2-positive invasive breast cancer patients and those after NAC among patients who did not achieve pathological complete response (pCR) using conventional adjuvant trastuzumab.
Journal ArticleDOI
Time trends for small gastric cancer in Japan.
Naoko Tsuji,Shingo Ishiguro,Masayuki Mano,Tsutomu Kasugai,Yasuko Nishizawa,Kuninori Nose,Isao Miyashiro,Masahiro Hiratsuka,Hiroshi Furukawa +8 more
TL;DR: The rate of tubular adenocarcinomas containing gastric type mucin has increased over time in small gastric cancer, suggesting that tubularAdenocARCinoma with gastric-type mucin changes into poorly differentiated adenOCarcinoma as tumors grow to advanced stages.
Journal ArticleDOI
Fibroblast-dependent differentiation/proliferation of mast cells.
TL;DR: Mice of W/Wv, Sl/Sld or mi/mi genotype are deficient in mast cells, but since T cell-dependent differentiation and proliferation of mast cells are intact in these mutant mice, mast cells do develop when bone marrow cells of these mutant animals were cultured in the presence of Tcell-derived growth factors.
Journal ArticleDOI
Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching
Noriko Fujita,Koichi Fujita,Seung-Jin Kim,Chikage Iguchi,Takashi Nomura,Toyokazu Aono,Tetsu Yanagisawa,Yukie Enomoto,Keiko Inakami,Yoshimasa Miyagawa,Riki Tomoike,Tsutomu Kasugai,Eiichi Shiba +12 more
TL;DR: Responsible omission of anthracycline may be an option for HER2-positive early breast cancer patients receiving neoadjuvant taxane and trastuzumab with good response in order to avoid overtreatment.
Journal ArticleDOI
A case of retroperitoneal bronchogenic cysts with malignant regeneration
Hidetoshi Eguchi,Hiroaki Ohigashi,Osamu Ishikawa,Tsutomu Kasugai,Shigekazu Yokoyama,Yo Sasaki,Isao Miyashiro,Yuichiro Doki,Kohei Murata,Shingi Imaoka +9 more
TL;DR: Familiarity, ease of access, trust, and awareness of benefits and risks are important.